Green tea extract, epigallocatechin-3-gallate, inhibits the growth and invasive ability of human glioma cells

WEI ZHANG and JIANPING JIA

Department of Neurology, Xuan Wu Hospital of the Capital University of Medical Sciences, 45 Changchun Street, Beijing 100053, P.R. China

Received March 17, 2008; Accepted May 23, 2008

DOI: 10.3892/mmr_0000021

Abstract. Epigallocatechin-3-gallate (EGCG) is a major constituent of green tea, but its effects on glioma cell growth have not been reported. The aim of this study was to investigate the anticancer effect of EGCG on the growth and invasive ability of glioma cells, as well as the molecular mechanisms responsible for it. Two glioma cell lines were treated with EGCG, and its effect on cell proliferation and invasive ability was studied using the MTT, Matrigel invasion and 3-D collagen colony forming assays. Our results demonstrate that EGCG treatment leads to a decrease in cell viability and the S-phase cell fraction in a dose-dependent manner. In addition, invasive ability was significantly suppressed in the EGCG-treated cells. Furthermore, the anticancer effect of EGCG was associated with increased expression of p27 and E-cadherin. Our results suggest that EGCG is a potential anticancer agent against glioma, and that its effect may be mediated through the upregulation of p27 and E-cadherin.

Introduction

Green tea is an aqueous infusion of dried unfermented leaves derived from the *Camellia sinensis* plant. It is a popular beverage in Asia, especially in China and Japan, and its consumption is associated with a reduced risk of several types of cancer, including that of the stomach, esophagus, prostate and lung (1). It has been reported that the quantity of green tea consumed affects its reduction of cancer risk and the delaying of cancer outbreak and recurrence. It acts as an antioxidant, antiproliferative, antitumor and anti-angiogenic agent, and is thus a novel candidate for chemoprevention (2). In addition, many studies using both animal models and human cancer cell lines have demonstrated that green tea has chemopreventive effects on a wide range of malignancies, human cancer cell lines have demonstrated that green tea has a wide range of anticancer activity against multiple cancer types. It contains many polyphenolic compounds, most abundant of which is the constituent known as epigallocatechin-3-gallate (EGCG), accounting for approximately 50% of the total polyphenol catechins (7). Mechanistic studies have indicated that EGCG exerts various anticancer effects, including the suppression of growth factor-mediated proliferation (8), the inhibition of transformation (9) and the repression of angiogenesis (10). *In vitro* studies have demonstrated that tea polyphenols, especially EGCG, cause growth inhibition and apoptosis in many types of human tumor cell lines, including melanoma, breast cancer, lung cancer, leukemia and colon cancer (11,12). This suggests that EGCG may also be a chemotherapeutic agent for the suppression of the growth of many types of human cancer.

Malignant gliomas are relatively uncommon but lethal cancers. Despite recent research efforts in cancer therapy, the prognosis for patients with malignant gliomas has remained poor. A combination of radiotherapy and chemotherapy has been used as a therapeutic approach, but patient response rates are low. Recently, it has been demonstrated that a combination of EGCG with radiation in human glioma cell lines leads to increased radiosensitivity (13). The aim of this study was to investigate the effect of EGCG on the growth and invasive ability of glioma cells. Two glioma cell lines were treated with EGCG, and the effect on cell proliferation and invasive ability was studied. Additionally, the molecular mechanisms responsible for this effect were investigated.

Materials and methods

Cell lines. Two glioma cell lines, U-138MG and U-251MG (American Type Culture Collection), were cultured in RPMI-1640 (Sigma) containing 5% FCS (Life Technologies Inc.), 0.03 mg/ml penicillin and 0.05 mg/ml streptomycin (Sigma) at 37˚C in a humidified atmosphere of 5% CO₂. Green tea epicatechin isomer (−)-EGCG with a purity of >95% was purchased from Sigma Chemical Co. (USA).

3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. Cells were seeded on a 96-well plate at a cell density of ~2000 cells/well, incubated overnight to allow cells to attach, and then incubated with different concentrations of EGCG (up to 200 μM) for 6 days. Following this, the medium was removed and cells were incubated with 1 mg/ml MTT solution for 4 h to allow the formation of a formazan precipi-
tate, subsequently dissolved in dimethyl sulfoxide. The absorbance in each well was read by a microplate reader at 540 nm.

Flow cytometric analysis. Floating and adherent cells were fixed in 1 ml 70% ethanol at -20°C for 12 h and stored. Cells were later rehydrated in 1 ml PBS pH 7.4 and stored at 4°C overnight. Prior to analysis, cells were treated with 0.5 μg/ml RNaseA (Sigma) and stained with propidium iodide (1 μg/ml) for 30 min at 37°C. Cell cycle analysis was conducted using the flow cytometer EPICS profile analyzer (Coulter, Miami, FL) and Modfit LT2.0 software (Verity Software House, Topsham, ME). Each experiment was repeated at least four times.

Matrigel invasion assay. To prepare an in vitro basement membrane, commercial cell culture invasion inserts (8-μm pore size; Millipore) were coated with Matrigel (120 μg/insert; Becton Dickinson) for 24 h. The assay was activated by the addition of 20,000 cells in 200 μl of 0.1% BSA-RPMI in the upper chamber with or without EGCG (100 μM), 400 μl fibronectin (10 μg/ml) and 400 μl 5% FCS RPMI in the lower chamber as the chemoattractant to induce invasion. Cells were incubated for 24 h at 37°C and 5% CO₂, and insert membranes were prepared for microscopic samples. Membranes were fixed for 10 min with 10% formaldehyde (J.T. Baker) and then stained with Mayer's hematoxylin (Zymed) and 1% aqueous eosin solution. The cells on the upper surface of the membrane were wiped off with cotton wool. After washing, the membranes were cut from the inserts and mounted with Depex. The number of cells on the lower surface of the membrane was counted using a PC-based image-analyzing system (Stereo Investigator) attached to a Nikon microscope with a x12.5 objective and x10 eyepieces. Representative areas of the invasive cells were photographed with a cooled color CCD camera (Optronics) and digitally stored on a desktop computer. Experiments were repeated three times, and each treatment was carried out in quadruplicate.

3-Dimension collagen colony forming assay. The cell suspension (200 μl; 3x10⁴ cells/ml) was mixed with 200 μl of cold rat tail collagen type I (3.60 mg/ml; BD Biosciences, MA). The mixed cell solution in collagen was plated as droplets in a 60-mm Petri-dish and air dried at room temperature. RPMI-1640 medium with 3% FCS with or without EGCG was added to each dish containing the semi-solid collagen-cell droplets. EGCG-treated and control samples were incubated at 37°C for 3-5 days. Cell morphology was observed using a phase contrast microscope, and images were captured under x200 magnification. A total of 500 colonies were counted in each experiment, and the percentage of colonies with elongated morphology was calculated. Each experiment was repeated at least three times. Error bars in figures indicate the standard deviation.

Western blot analysis. Protein was extracted with a modified radioimmunoprecipitation (RIPA) buffer (50 mM Tris-HCl;
pH 7.4), 1% NP-40, 1% Na-deoxycholate, 150 mM NaCl, 1 mM EDTA, 0.1% SDS, 1 mM Na3VO4 and 1 mM NaF) containing proteinase inhibitors (Complete Protease Inhibitor Cocktail Tablets, Roche). Protein concentrations were measured using the DC protein assay kit (Bio-Rad Laboratories Inc.). Proteins (20 μg) were separated by electrophoresis on a 12.5% SDS-polyacrylamide gel (SDS-PAGE) and blotted onto nitrocellulose membrane (Amersham Piscataway, NJ, USA). After blocking with 10% non-fat dry milk, the blots were respectively incubated with primary antibodies against p27, p53, p21 and E-cadherin (1:1000; BD Biosciences), and then incubated with horseradish peroxidase (HRP)-conjugated secondary antibody (Amersham). Signals were detected using ECL Plus Western blot detection reagents (Amersham).

**Statistical analysis.** The collected data were analyzed using one-way ANOVA followed by the Newman-Keuls multiple comparison test. Statistical analysis was performed using Prism version 3.0 statistical software (GraphPad Software, San Diego, CA). A p-value <0.05 was considered significant.

**Results**

**Effect of EGCG on proliferation of glioma cells.** Two glioma cell lines, U-138MG and U-251MG, were treated with 5 doses of EGCG, and the effect on cell growth rate was measured by MTT. As shown in Fig. 1, EGCG treatment led to decreased cell viability in a dose-dependent manner. U-138MG cells were also found to be slightly more sensitive to EGCG-induced growth suppression than U-251MG ones. To further confirm these results, we performed cell cycle analysis. As shown in Fig. 2, the S phase fraction of U-138MG cells was decreased from 22% at the 0 time-point to 14% after 48 h of EGCG treatment (25 μM). This decreased S phase cell fraction was correlated with an increase in G1 phase cells (from 59 to 69%). The results suggest that EGCG is able to suppress the growth of glioma cells in a dose- and time-dependent manner.

**Effect of EGCG on the invasive ability of glioma cells.** We investigated whether EGCG had any effect on the invasive ability of the U-138MG and U-251MG glioma cell lines. Matrigel invasion assay revealed that EGCG treatment led to the decreased ability of the cells to penetrate the cell culture filter membrane, suggesting that EGCG suppressed the invasion of glioma cells (Fig. 3A). Further analysis (Fig. 3B) showed that there was a significant decrease in the invasive ability of the EGCG-treated cells compared to the untreated control cells (p<0.05) in both lines, suggesting that EGCG suppressed the metastatic ability of these cells. To further confirm these results, we performed a 3-D collagen invasion assay. As shown in Fig. 4A, while the untreated cells grew inside the semi-solid collagen, a tightly packed colony was...
Discussion

In the present study, we demonstrated that EGCG treatment alone was able to suppress the growth of glioma cells. In addition, this growth inhibitory effect was mediated through both p53-dependent and -independent pathways. In the cells with wild-type p53, such as U-138MG, the EGCG-induced inhibitory effect was mediated through the activation of p53, which in turn led to the induction of p21 and subsequent cell cycle G1 phase arrest. In the cells with a p53 mutation, such as the U-251MG cells, the EGCG-induced growth suppression may have been mediated through p53-independent upregulation of p27, a CDK inhibitor which plays a key role in the induction of cell cycle G1 phase arrest. Our results provide evidence to suggest that EGCG may act as an agent against the growth of glioma cells. It has been reported that EGCG is able to induce radiosensitivity in glioma cells (13). Our results in this study suggest that EGCG could be used as a single agent to achieve an anticancer effect. The anticancer effect of EGCG has been reported in several types of cancers (16-18).

In this study, we provided evidence to suggest that EGCG may act as an agent against the induction of cell cycle G1 phase arrest. Our results provide evidence that EGCG may act as an agent against the growth of glioma cells. It has been reported that EGCG is able to induce radiosensitivity in glioma cells (13). Our results in this study suggest that EGCG could be used as a single agent to achieve an anticancer effect. The anticancer effect of EGCG has been reported in several types of cancers (16-18). In this study, we provided evidence to suggest that its action is not dependent on a functional p53 in glioma cells. Therefore, it is possible that EGCG may be a potential effective agent for the treatment of advanced cancers.

Metastasis is one of the main causes of cancer-related death, and the suppression of cancer invasion is consistently a main target for the development of new anticancer drugs. In this study, we found that EGCG treatment reduced invasive ability and restored E-cadherin expression in both our cell lines. Since E-cadherin downregulation is one of the commonly observed characteristics in metastatic cancers, it is possible that the anti-metastatic effect of EGCG is regulated through the upregulation of E-cadherin. It has been reported that EGCG is able to upregulate E-cadherin in an animal model of intestinal cancer (19). The present study was the first to demonstrate this effect in human glioma cells, though the mechanism behind this upregulation has yet to be elucidated. EGCG has also been reported to reactivate E-cadherin gene expression through the removal of methylation in the promoter region of the E-cadherin gene. Since upregulation of E-cadherin has been suggested as a therapeutic target for the treatment of metastatic cancer, our results suggest that EGCG has potential as an anticancer drug capable of inhibiting the invasive ability of glioma cells.

In summary, we established the potential anticancer effect of EGCG on two glioma cancer cell lines, and demonstrated its effect on the suppression of cancer cell growth and invasive ability. This may be mediated through the induction of cell cycle G1 phase arrest and the upregulation of E-cadherin. Our results suggest the novel therapeutic potential of EGCG for the treatment of advanced glioma.

References


